Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+T-Cell Responses in Mice
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
We recently discovered an expanded family of adeno-associated viruses (AAVs) that show promise as improved gene therapy vectors. In this study we evaluated the potential of vectors based on several of these novel AAVs as vaccine carriers for human immunodeficiency virus type 1 Gag. Studies with mice indicated that vectors based on AAV type 7 (AAV7), AAV8, and AAV9 demonstrate improved immunogenicity in terms of Gag CD8+T-cell and Gag antibody responses. The quality of these antigen-specific responses was evaluated in detail for AAV2/8 vectors and compared to results with an adenovirus vector expressing Gag (AdC7). AAV2/8 produced a vibrant CD8+T-cell effector response characterized by coexpression of gamma interferon and tumor necrosis factor alpha as well as in vivo cytolytic activity. No CD8+T-cell response generated by any of the AAVs was effectively boosted with AdC7, a result consistent with the finding of a relative lack of cells expressing interleukin-2 (IL-2) or a central memory phenotype at 3 months after the prime. The primary response to an AdC7 vaccine differed from that generated by AAVs in that the peak effector response evolved into populations of Gag-specific T cells expressing high levels of cytokines, including IL-2, and with effector memory and central memory phenotypes. A number of mechanisms could be considered to explain the aberrant activation of CD8+T cells by AAV, including insufficient inflammatory responses, CD4 help, and/or chronic antigen expression and T-cell exhaustion. Interestingly, the B-cell response to AAV-encoded Gag was quite vibrant and easily boosted with AdC7.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Capsids with less transduction efficiency in APCs potentially have lower risk of induction of an immune response against the transgene [134–136].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [136]
Citations
Cites
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“It is also possible that there is inadequate CD4 T-cell help in the setting of AAV gene transfer, which is a step that is more important for the formation of memory than the initial CD8 T-cell effector response (19, 30).”
BackgroundWherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Self-citationRequirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Shiver, J. W., Fu, T.-M., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z.-Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,176
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationAdenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Hoggan, M. D., Blacklow, N. R., & Rowe, W. P. (1966) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.55.6.1467 · Cited by 536
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 1×
“A paucity of both CD8 T-cell and B-cell responses to transgene products is observed when AAV vectors are targeted to the liver (9, 26).”
BackgroundRutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Research works printed but not linked: 1
- 10.1172/JCI200316887 · doi:10.1172/jci200316887 · Paper page
Cited by
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Replicating and non-replicating viral vectors for vaccine development
Robert-Guroff, M. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.010 · Cited by 275
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Vandenberghe, L. H., Xiao, R., Lock, M., Lin, J., Korn, M., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.107 · Cited by 151
“Tetramer staining was performed as described previously (J. Lin et al. , 2007).”
Self-citationSystematic Evaluation of AAV Vectors for Liver directed Gene Transfer in Murine Models
Wang, L., Wang, H., Bell, P., McCarter, R. J., He, J., Calcedo, R., Vandenberghe, L. H., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.246 · Cited by 139
Self-citationThe Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 125
Self-citationPloquin, A., Szécsi, J., Mathieu, C., Guillaume, V., Barateau, V., Ong, K. C., Wong, K. T., Cosset, F., Horvat, B., & Salvetti, A. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis699 · Cited by 117
AAV Vectors Vaccines Against Infectious Diseases
Nieto, K., & Salvetti, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00005 · Cited by 100
Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., & Wilson, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803965 · Cited by 99
Self-citationArimura, S., Okada, T., Tezuka, T., Chiyo, T., Kasahara, Y., Yoshimura, T., Motomura, M., Yoshida, N., Beeson, D., Takeda, S., et al. (2014) · Science · doi:10.1126/science.1250744 · Cited by 92
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
“Some studies showed that CD8 T cell responses induced by an AAV vector-encoded transgene are defective in mice: T cells do not proliferate upon re-exposure to their antigen in vivo, they only produce low levels of cytokines and they fail to protect against a surrogate pathogen (57, 58).”
BackgroundDOK7 gene therapy enhances motor activity and life span in ALS model mice
Miyoshi, S., Tezuka, T., Arimura, S., Tomono, T., Okada, T., & Yamanashi, Y. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607298 · Cited by 80
A New Genetic Vaccine Platform Based on an Adeno-Associated Virus Isolated from a Rhesus Macaque
Lin, J., Calcedo, R., Vandenberghe, L. H., Bell, P., Somanathan, S., & Wilson, J. M. (2009) · Journal of Virology · doi:10.1128/jvi.01441-09 · Cited by 66
Self-citationMays, L. E., Wang, L., Lin, J., Bell, P., Crawford, A., Wherry, E. J., & Wilson, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2013.134 · Cited by 62
Self-citationViral vectors as vaccine carriers
Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 65
Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction
Shin, J.-H., Nitahara‐Kasahara, Y., Hayashita‐Kinoh, H., Ohshima-Hosoyama, S., Kinoshita, K., Chiyo, T., Okada, H., Okada, T., & Takeda, S. (2011) · Gene Therapy · doi:10.1038/gt.2011.36 · Cited by 64
Lin, J., Calcedo, R., Vandenberghe, L. H., Figueredo, J. M., & Wilson, J. M. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.033 · Cited by 53
Self-citationYuan, F., Banner, D., Kelvin, A. A., Huang, S. S. H., Paige, C. J., Corfe, S. A., Kane, K. P., Bleackley, R. C., Rowe, T., Leon, A. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05540-11 · Cited by 53
Huang, J., Li, X., Coelho-dos-Reis, J. G. A., Wilson, J. M., & Tsuji, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088205 · Cited by 56
Self-citationVelazquez, V. M., Bowen, D. G., & Walker, C. M. (2009) · Blood · doi:10.1182/blood-2008-01-131375 · Cited by 46
Nieto, K., Stahl-Hennig, C., Leuchs, B., Müller, M., Gissmann, L., & Kleinschmidt, J. A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.202 · Cited by 46
“A possible disadvantage of such a depot function is T-cell exhaustion, which has been observed for rAAV2 vectors ( J. Lin et al., 2007; S.W. Lin et al., 2007).”
BackgroundThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Regulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
Self-citationJoniec-Maciejak, I., Ciesielska, A., Wawer, A., Sznejder-Pachołek, A., Schwenkgrub, J., Cudna, A., Hadaczek, P., Bankiewicz, K., Członkowska, A., & Członkowski, A. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.03.008 · Cited by 40
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Sipo, I., Knauf, M., Fechner, H., Poller, W. C., Planz, O., Kurth, R., & Norley, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.12.037 · Cited by 38
Krotova, K. Y., Day, A., & Aslanidi, G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.001 · Cited by 32
Muscle‐directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors
Wang, L., Louboutin, J. P., Bell, P. L., Greig, J. A., LI, Y., WU, D., & Wilson, J. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04491.x · Cited by 33
Self-citationZhou, L., Zhu, T., Ye, X., Yang, L., Wang, B., Liang, X., Lü, L., Tsao, Y., Chen, S., Li, J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.139 · Cited by 31
Li, X., Cao, H., Wang, Q., Di, B., Wang, M., Lu, J., Pan, L., Yang, L., Mei, M., Pan, X., et al. (2012) · Microbes and Infection · doi:10.1016/j.micinf.2012.05.002 · Cited by 26
Sun, X., Li, M., Jiang, Y., Zhang, Z., & Xu (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s43827 · Cited by 23
Liu, Q., Huang, W., Zhao, C., Zhang, L., Meng, S., Gao, D., & Wang, Y. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23647 · Cited by 24
Adriouch, S., Franck, E., Drouot, L., Bonneau, C., Jolinon, N., Salvetti, A., & Boyer, O. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00199 · Cited by 22
Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine
Rosa, D. S., Ribeiro, S. P., Fonseca, S. G., Almeida, R. R., Santana, V. C., Apostólico, J. D. S., Kalil, J. E., & Cunha‐Neto, E. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0101 · Cited by 22
Zhu, F., Wang, Y., Xu, Z., Qu, H., Zhang, H., Niu, L., Xue, H., Jing, D., & He, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9739 · Cited by 22
Lin, J., Somanathan, S., Roy, S., Calcedo, R., & Wilson, J. M. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.053 · Cited by 21
Self-citationPreclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Nieto, K., Kern, A., Leuchs, B., Gissmann, L., Müller, M., & Kleinschmidt, J. A. (2009) · Antiviral Therapy · doi:10.3851/imp1469 · Cited by 22
GFP expression by intracellular gene delivery of GFP-coding fragments using nanocrystal quantum dots
Hoshino, A., Manabe, N., Fujioka, K., Hanada, S., Yasuhara, M., Kondo, A., & Yamamoto, K. (2008) · Nanotechnology · doi:10.1088/0957-4484/19/49/495102 · Cited by 16
Xu, D., & Walker, C. M. (2011) · Journal of Virology · doi:10.1128/jvi.05375-11 · Cited by 14
Hippocampal GAD67 Transduction Using rAAV8 Regulates Epileptogenesis in EL Mice
Shimazaki, K., Kobari, T., Oguro, K., Yokota, H., Kasahara, Y., Murashima, Y. L., Watanabe, E., Kawai, K., & Okada, T. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.012 · Cited by 15
Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer
Pandya, M., Britt, K., Hoffman, B. E., Ling, C., & Aslanidi, G. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000093 · Cited by 14
Cesco-Gaspere, M., Zentilin, L., Giacca, M., & Burrone, Ó. R. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02119.x · Cited by 15
Yun, S.-I., Song, B.-H., Koo, Y., Jeon, I., Byun, S. J., Park, J.-H., Joo, Y.-S., Kim, S.-Y., & Lee, Y.-M. (2009) · Virus Research · doi:10.1016/j.virusres.2009.04.014 · Cited by 10
Logan, G. J., Wang, L., Zheng, M., Coppel, R. L., & Alexander, I. E. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.92 · Cited by 8
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
Okada, H., Ishibashi, H., Hayashita‐Kinoh, H., Chiyo, T., Nitahara‐Kasahara, Y., Baba, Y., Watanabe, S., Takeda, S., & Okada, T. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.21 · Cited by 9
Ghenassia, A., Gross, D., Lorain, S., Tros, F., Urbain, D., Benkhelifa‐Ziyyat, S., Charbit, A., Davoust, J. M., & Chappert, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.019 · Cited by 9
Autoimmunity, Recessive Diseases, and Gene Replacement Therapy
Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.253 · Cited by 6
Self-citationJournou, M., Devaux, M., Jaulin, N., Pichard, V., Segovia, M., Moreau, A., Duff, J. L., Cuturi, M. C., Guilbaud, M., & Adjali, O. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101409 · Cited by 8
Zhu, Q.-X., Zhang, Y., Zhang, H., Leng, C., Deng, C.-L., Wang, X., Li, J.-J., Ye, X.-L., Zhang, B., & Li, X. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012604 · Cited by 6
Teaching an old vector new tricks: the surprising versatility of AAV vaccines
Winston, S. M., Wiggins, K., Schultz‐Cherry, S., & Davidoff, A. M. (2025) · Journal of Virology · doi:10.1128/jvi.00730-25 · Cited by 4
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 6
Jiang, B., Li, Q., Du, Y., Peng, N., Chen, L., Chen, Z., & Chen, X. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.075 · Cited by 3
Safety of Adeno-Associated Viral Vectors
Lin, S., & Ertl, H. C. J. (2008) · Future Virology · doi:10.2217/17460794.3.5.491 · Cited by 3
Delivery of gene-expressing fragments using quantum dot
Hoshino, A., Manabe, N., Hanada, S., Fujioka, K., Yasuhara, M., Kondo, A., & Yamamoto, K. (2009) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.808775 · Cited by 2
The Role of Natural-Based Biomaterials in Advanced Therapies for Autoimmune Diseases
Ferreira, H., Fangueiro, J. F., & Neves, N. M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0947-2_8 · Cited by 2
Muscle as a Target for Genetic Vaccine
Zhi, Y., & Gao, G. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_14 · Cited by 1
Self-citationVaccines & Vaccine Technologies
(2014) · OMICS International eBooks · doi:10.4172/978-1-63278-004-1-005 · Cited by 1
AIDS Vaccines: the Unfolding Story
Norley, S. (2014) · ASM Press eBooks · doi:10.1128/9781555816872.ch48
Characterization of Host Protective Immunity against Influenza Infection in Ferrets and Mice
Yuan, F. (2013) · TSpace (University of Toronto)
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
Chand, A. (2012) · Mspace (University of Manitoba)
The adeno associated viral vectored Dp12S vaccine effective alleviation of asthma symptoms in mice
Liu, S., Chu, J., Yin, X., Xiong, A., Luo, Y., Xin, J., He, Z., & Qin, S. (2025) · npj Vaccines · doi:10.1038/s41541-025-01311-w
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Jeanpierre, L., Pecquet, C., Saliba, H., Finard, P., Terry, S., Tavella, G., Guesmia, I., Boutin, S., Bertin, B., Benkhelifa‐Ziyyat, S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202541
Metadata
- Authors
- Lin, J., Zhi, Y., Mays, L., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2007-11
- Volume
- 81
- Issue
- 21
- Pages
- 11840-11849
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2168776
- OpenAlex
- W2123634260
- Cited by
- 66
- References
- 44
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 2 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 4
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus vectors, CD8+ T cell responses, AAV8, AAV9, adenoviral vector, vaccine immunogenicity, T cell exhaustion, central memory T cells, interleukin-2, B cell response
- MeSH terms
- Dependovirus, Animals, B-Lymphocytes, Genetic Vectors, Interleukin-2, Liver, Lung, Mice, Inbred BALB C, Mice, Inbred C57BL, Tumor Necrosis Factor-alpha, HIV-1, HIV Infections, Gene Products, gag, AIDS Vaccines, CD8-Positive T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.